Efficacy of early single low dose of rituximab in prophylaxis of EBV reactivation and EBV related post-transplant lymphoproliferative disorder after allogeneic hematopoietic cell transplantation (ASH 2025) - Dec 5, 2025 - "All patients received ATG based conditioning, and letermovir for CMV prophylaxis. Our study shows that early single low dose of rituximab after allo-HCT can significantly reduce incidence of EBV viremia and the risk of EBV-related PTLD, without severe adverse effect despite delayed humoral immune reestablishment. It will provide an effective prophylactic strategy for patients at high risk of EBV and reduce transplant-related mortality after allo-HCT."
Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Aplastic Anemia • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Transplantation
|
|
Fang Liu 1,2; Yecheng Li 1; Gele Tong 2; Lina Feng 2; Jing Wu 1; Yu Sun 2; Min Chen 1; Peihua Lu 2
|